Continuous vs. Cyclical HRT: Understanding Your Treatment Schedule

October 5, 2026

Continuous vs. Cyclical HRT: Regimens Explained is a practical guide to the two common treatment schedules used in menopause hormone therapy. This article explains how each regimen works, what to expect for bleeding, and when to follow up with your clinician.

Key takeaways
There are two main HRT schedules: continuous (combined continuous) and cyclical (sequential).
Bleeding patterns differ by regimen and by where you are in the menopause transition.
Regular review is important—seek assessment for new, persistent, or heavy bleeding.
Talk with your healthcare provider about risks and benefits to choose the right schedule for you.

Why treatment schedule matters

How you take HRT—continuously or in cycles—affects symptom control, bleeding, and long-term safety considerations. The choice is based on your menopausal stage (perimenopause, early postmenopause, or established postmenopause), personal preferences, response to treatment, and medical history. If you’re just starting HRT during perimenopause, your doctor may recommend a different schedule than they would for someone several years past their final menstrual period.

Definitions: continuous vs. cyclical (sequential) HRT

What is continuous HRT?

Continuous HRT means you take estrogen every day and a progestogen (if needed) every day as well, without planned breaks. This is often called combined continuous HRT. With continuous treatment, monthly bleeding usually stops within a few months for most people who are already a year or more since their last period.

What is cyclical (sequential) HRT?

Cyclical or sequential HRT means estrogen is taken every day, but progestogen is given in a scheduled block each month (for example, for 10–14 days each month). This sequence causes a predictable withdrawal bleed during the progestogen-free interval, similar to a monthly period. Sequential HRT is commonly used for people who are still having irregular bleeding or are within a year or two of their last period.

Conceptual schedule comparison (no dosing details)

The following conceptual comparison explains timing and typical bleeding patterns without giving dose instructions.

Continuous combined HRT
- Estrogen: taken daily without interruption.
- Progestogen: taken daily (in combined preparations) without interruption.
- Bleeding: initially may have irregular spotting or bleeding for the first 3–6 months; most people stop having monthly bleeding after several months.
- Best for: people who prefer no monthly bleed and for many who are at least 12 months post-final menstrual period.
Cyclical (sequential) HRT
- Estrogen: taken daily without interruption.
- Progestogen: taken for a defined number of days each month (e.g., mid-to-late part of each month).
- Bleeding: predictable monthly withdrawal bleeding during each progestogen-free or post-progestogen phase—may start as irregular but usually becomes regular.
- Best for: people who are still in perimenopause or within a short time after their last period and want predictable monthly bleeding.

Expected bleeding and what it means

Bleeding on HRT is common, especially during the first few months after starting or changing treatment. Understanding what is typical can reduce anxiety and help you know when to seek medical review.

Early months (first 3 months)

Spotting and light irregular bleeding are common for the first 3 months with either continuous or cyclical HRT. The body is adjusting to hormones, and the uterine lining may take time to stabilize.

3–6 months

With sequential regimens, monthly withdrawal bleeding should become predictable and lighter for many people. With continuous combined regimens, bleeding and spotting usually reduce and often stop by about 3–6 months; however, intermittent spotting may persist in some people.

After 6 months

Persistent or heavy bleeding beyond 6 months is not typical and should be checked. New bleeding after a period of no bleeding (for example, new bleeding after 12 months or more without bleeding on a continuous regimen) also requires assessment. See further guidance about when to get checked for bleeding while taking HRT.

How clinicians decide which schedule to use

Clinicians consider several factors when choosing a regimen:

Menopausal stage: People who are still in perimenopause often use sequential regimens to match the ongoing cycles; those who are at least 12 months after their last period are often offered continuous combined HRT.
Bleeding preference: Some people prefer predictable monthly bleeding (sequential); others prefer no monthly bleeding (continuous).
Medical history: Breast cancer risk, clotting disorders, liver disease, or uncontrolled blood pressure influence HRT type and schedule. Some conditions mean HRT is not recommended.
Response and side effects: If bleeding or other side effects occur, schedules may be adjusted or an alternative approach tried.

Benefits, risks and side effects

Both continuous and cyclical regimens can effectively treat menopausal symptoms such as hot flashes, night sweats, mood changes, and vaginal dryness. Estrogen remains the most effective treatment for many symptoms; progestogen protects the lining of the uterus when a woman has an intact uterus.

Benefits

Relief of vasomotor symptoms (hot flashes, night sweats).
Improved sleep, mood, and quality of life for many users.
Reduced risk of bone loss and fractures when systemic estrogen is used in appropriate candidates.
Sequential regimens may be preferred to preserve a monthly bleeding pattern during transition; continuous regimens may reduce or eliminate monthly bleeding for those beyond menopause.

Common side effects

Breast tenderness, bloating, fluid retention.
Mild nausea or headaches when starting therapy.
Irregular spotting or bleeding, particularly in the first months.
Mood changes or changes in libido for some people.

Risks to consider

Current guidance from organizations such as the North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), and NICE emphasizes individualized assessment. Key points include:

Combined estrogen-progestogen therapy slightly increases the risk of breast cancer compared with non-use over several years; duration and type of progestogen influence risk.
Systemic estrogen increases the risk of venous thromboembolism (blood clots) and stroke, particularly in older age and with oral preparations; baseline risk factors matter.
HRT is generally prescribed at the lowest effective dose for symptom control and regularly reviewed, balancing benefits and risks.
HRT is contraindicated in women with certain conditions such as active breast cancer, unexplained vaginal bleeding that has not been evaluated, uncontrolled hypertension, recent stroke or heart attack, or active liver disease. Individual circumstances vary, so discuss your history with a clinician.

When bleeding should prompt assessment

While some bleeding is expected early on, certain patterns require prompt medical review. Seek assessment if you experience any of the following:

Bleeding that is heavy (soaking through sanitary protection), prolonged, or worsening.
Bleeding that continues beyond 6 months after starting a regimen, especially with continuous combined HRT.
New bleeding after a long period without bleeding (for example, new bleeding after 12 months or more of amenorrhea on continuous therapy).
Bleeding accompanied by pain, fever, unusual discharge, rapid weight loss, or other concerning symptoms.

Guidance and pathways for evaluation may include a pelvic exam, ultrasound, or specialist referral depending on your age, risk factors, and the bleeding pattern. For practical advice about when to get checked, see our page on bleeding while taking HRT.

Adjusting treatment: common options without dosing

If bleeding or side effects occur, clinicians may take several non-dosing steps to help:

Continue the chosen regimen for several months if bleeding is light—many changes settle with time.
Switch between sequential and continuous schedules depending on bleeding pattern and preference.
Change the type of progestogen or use an intrauterine device that releases progestogen to reduce uterine bleeding for some people.
Investigate other causes of bleeding, such as polyps, fibroids, or endometrial changes, and treat as indicated.

Understanding the role of progestogens may help explain some adjustments; learn more about the role of progesterone in HRT and why it is used with estrogen when the uterus is present.

Who should not use HRT or needs special evaluation?

HRT is not suitable for everyone. It should be avoided or used with caution in people with certain medical conditions. Notify your clinician if you have any of the following:

Current or past hormone-sensitive cancers (for example, breast cancer) without specialist approval.
Unexplained vaginal bleeding that has not been investigated.
Active liver disease or significantly abnormal liver function tests.
Uncontrolled high blood pressure, recent stroke, or recent heart attack.
Known blood clotting disorders, prior venous thromboembolism, or strong family history of clots.
Pregnancy—HRT is not appropriate during pregnancy.

Even if you have some risk factors, a specialist may sometimes recommend tailored treatment after careful assessment. Always be open with your provider about your full medical history and family history so they can determine the safest plan.

Shared decision-making and follow-up

Choosing a regimen is a shared decision between you and your provider. Consider these practical steps:

Discuss your symptoms, menopausal stage, and goals (for example, desire to avoid monthly bleeding or to have predictable cycles).
Review your medical history and baseline risk factors for breast cancer, heart disease, stroke, and blood clots.
Agree on a regimen and set expectations for bleeding and side effects.
Plan follow-up—many clinicians review at 3 months, then annually, or sooner if problems arise.

Follow-up allows reassessment of benefits, side effects, and any new risk factors. If your bleeding pattern is problematic or you experience side effects, talk with your clinician about alternative schedules or treatments.

Frequently Asked Questions

1. If I start continuous HRT, will I definitely stop having periods?

Not necessarily. Many people stop monthly bleeding within 3–6 months on continuous combined regimens, but some may continue to have irregular spotting for longer. If bleeding persists beyond 6 months, it should be evaluated.

2. Can I switch between cyclical and continuous HRT?

Yes. Switching is common—your provider may recommend changing regimens if bleeding patterns are unacceptable, if you move from perimenopause into postmenopause, or if side effects occur. Discuss timing and expectations with your clinician.

3. Is bleeding on HRT a sign of cancer?

Most bleeding on HRT is related to the hormones and not cancer, especially early after starting treatment. However, persistent, heavy, or new bleeding warrants evaluation to rule out other causes, including endometrial pathology. Don’t ignore concerning bleeding—seek assessment.

4. How long should I try a regimen before deciding it isn’t working?

Give most regimens about 3 months to see if side effects and bleeding settle; some benefits and side effects may take longer. If bleeding is heavy or concerning, seek earlier review. Your clinician will help judge whether to continue, change the schedule, or investigate further.

5. Can I use an intrauterine progestogen device instead of taking progestogen tablets?

An intrauterine progestogen-releasing device is an option for some people and can reduce uterine bleeding while providing endometrial protection. Whether it is appropriate depends on individual factors and should be discussed with your provider.

Conclusion

Choosing between continuous and cyclical HRT depends on your menopausal stage, bleeding preferences, medical history, and tolerance of side effects. Sequential (cyclical) regimens provide predictable monthly bleeding and are often used during perimenopause, while continuous regimens reduce or eliminate monthly bleeding for many people beyond menopause. Regular follow-up and prompt assessment of persistent or heavy bleeding are important. Work with your healthcare provider to select the schedule that best fits your needs, review the risks and benefits, and adjust treatment when necessary.

Medical disclaimer: This article is for general educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Hormone therapy is not right for everyone. Always talk to your doctor or another qualified healthcare provider about your symptoms, health history and treatment options before starting, stopping or changing any medication.